Indication:Female hypoactive sexual desire disorder
Place in Therapy
Intrinsa is the only licensed product for women with HSDD. Its use is restricted to a narrow population: women who have had a bilateral oophorectomy and hysterectomy on con comomitant oestrogen with symptoms of HSDD. This diagnosis can only be made many months after surgery once the patients’ normal activities are resumed. HSDD is complex. Diagnosis requires a full psychological and medical assessment by a specialist.
Treatment should be stopped if no response is seen within 3 to 6 months.
There are concerns about long-term safety of Intrinsa regarding CVS effects, effects on the breast and endometrial safety (if used in non-hysterectomised women).